Baker Bros. Advisors 13F: New $11M Stake in Evommune (EVMN)
A newly filed disclosure reveals the healthcare-focused investment firm established a stake in the clinical-stage biotech.
Reviewed by automated data checks against the source filing. How we make and check alerts
Baker Bros. Advisors opened a new position of 847,390 shares in Evommune, Inc. ($EVMN), according to a 13F filing with the SEC dated May 15, 2026. It reported 847,390 shares worth $11.26 million at the end of the quarter.
Since the filing, $EVMN is down 0.2% after 1 week, down 9.1% after 1 month and down 77.4% to date (from the $22.92 close on May 15, 2026).
Find the original: Baker Bros. Advisors 13F filings on SEC EDGAR
EVMN
Evommune, Inc.
Key Points
- Baker Bros. Advisors acquired 847,390 shares of Evommune, Inc. during the first quarter, representing a brand-new position.
- Evommune stock closed at $13.29 on Sunday, trading well above its 52-week low of $9.20 but down from its peak of $33.20.
- Eight Wall Street analysts follow the stock, giving Evommune a consensus buy recommendation with a target mean price of $24.13.
Get $EVMN trade alerts by text
We text you when insiders, Congress or big funds trade $EVMN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Evommune, Inc. alert may contain errors. Disclosures
Baker Bros. Advisors acquired a brand-new stake in Evommune, Inc. (NYSE: EVMN) during the first quarter of 2026. The institutional investment firm disclosed its new position of 847,390 shares in a Form 13F filing with the SEC on May 15, 2026.
Details on the Evommune Transaction
Baker Bros. Advisors initiated its position in Evommune with the purchase of 847,390 shares. The investment was valued at approximately $11.26 million at the close of the first quarter. Because this is a newly established position, there is no prior-period share count to compare it against.
Evommune Stock Performance Post-Filing
Evommune shares closed at $13.29 on Sunday. The stock has experienced a volatile path since the quarter ended, trading within a 52-week range of $9.20 to $33.20. While the shares remain above their 50-day moving average of $12.31, they have not yet reclaimed their longer-term 200-day moving average of $19.45.
Recent Earnings
Evommune reported revenue of $10.0 million for its most recent fiscal period. The company is currently pre-profit, showing a net loss with an earnings per share (EPS) of -$11.83 and a return on equity of -52.1%. Shareholders are looking toward November 16, 2026, when the company is scheduled to report its next round of quarterly financial results.
Analysts Set New Price Targets
Several research firms have updated their outlooks on Evommune. UBS started coverage on October 12, 2026, setting a Neutral rating with an $8.00 target. On September 9, 2026, Leerink Partners maintained its Outperform rating and adjusted its price target to $22.00, while RBC Capital held its Outperform rating with a $21.00 price target. Earlier in the summer, Needham started coverage with a Buy rating and a $28.00 target on August 26, 2026. Currently, eight analyst opinions yield a consensus buy recommendation for the stock, with a consensus target price of $24.13.
About Evommune, Inc.
Evommune is a Palo Alto, California-based biotechnology firm developing clinical-stage therapies for chronic inflammatory diseases. The company is currently testing treatments for conditions such as eczema, chronic hives, and inflammatory bowel disease. Its pipeline is designed to target the specific cellular pathways that trigger these chronic conditions.
What's Ahead for Evommune, Inc.
Market observers will be watching the progress of Evommune's upcoming clinical trials and its next financial report on November 16, 2026. Because Form 13F filings are backward-looking documents published 45 days after the quarter ends, these figures represent the fund's holdings as of March 31, 2026, and may not reflect its current portfolio.
Related Filing Alerts
Source: Baker Bros. Advisors's 13F filing on $EVMN (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Baker Bros. Advisors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts